PT1480646E - Agentes anti-infecciosos e/ou imunomoduladores para terapia preventiva após acidentes vasculares cerebrais graves - Google Patents

Agentes anti-infecciosos e/ou imunomoduladores para terapia preventiva após acidentes vasculares cerebrais graves Download PDF

Info

Publication number
PT1480646E
PT1480646E PT03714776T PT03714776T PT1480646E PT 1480646 E PT1480646 E PT 1480646E PT 03714776 T PT03714776 T PT 03714776T PT 03714776 T PT03714776 T PT 03714776T PT 1480646 E PT1480646 E PT 1480646E
Authority
PT
Portugal
Prior art keywords
infective agents
preventive therapy
cerebrovascular accident
agents
therapy following
Prior art date
Application number
PT03714776T
Other languages
English (en)
Inventor
Andreas Meisel
Konstantin Prass
Christian Meisel
Elke Halle
Ulrich Dirnagl
Hans Dieter Volk
Original Assignee
Charite Universitaetsmedizin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charite Universitaetsmedizin filed Critical Charite Universitaetsmedizin
Publication of PT1480646E publication Critical patent/PT1480646E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT03714776T 2002-03-05 2003-03-05 Agentes anti-infecciosos e/ou imunomoduladores para terapia preventiva após acidentes vasculares cerebrais graves PT1480646E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10210536 2002-03-05
DE10218328A DE10218328A1 (de) 2002-03-05 2002-04-24 Mittel zur präventiven Therapie nach akutem Schlaganfall

Publications (1)

Publication Number Publication Date
PT1480646E true PT1480646E (pt) 2008-11-03

Family

ID=27789739

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03714776T PT1480646E (pt) 2002-03-05 2003-03-05 Agentes anti-infecciosos e/ou imunomoduladores para terapia preventiva após acidentes vasculares cerebrais graves

Country Status (15)

Country Link
US (1) US8673934B2 (pt)
EP (1) EP1480646B1 (pt)
JP (1) JP2005525361A (pt)
CN (1) CN1652785A (pt)
AT (1) ATE402702T1 (pt)
AU (1) AU2003219016B2 (pt)
BR (1) BRPI0308256A2 (pt)
CA (1) CA2478133A1 (pt)
DE (2) DE10218328A1 (pt)
DK (1) DK1480646T3 (pt)
ES (1) ES2311093T3 (pt)
MX (1) MXPA04008573A (pt)
PT (1) PT1480646E (pt)
RU (1) RU2327454C2 (pt)
WO (1) WO2003074057A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005053679A1 (de) * 2005-06-24 2006-12-28 Bayer Healthcare Ag Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
DE102007020152A1 (de) * 2007-04-26 2008-10-30 Charité - Universitätsmedizin Berlin Mittel zur antiinfektiven Behandlung eines Patienten
US9598488B2 (en) * 2008-02-01 2017-03-21 Albany Medical College Blockage of interferon-gamma for prevention of polymicrobial synergy
RU2571282C1 (ru) * 2014-05-22 2015-12-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Способ лечения инсульта
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN110964778B (zh) * 2018-09-29 2024-02-23 南方医科大学珠江医院 肠杆菌科作为缺血性脑卒中生物标志物的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4437868A1 (de) * 1994-10-22 1996-04-25 Boehringer Ingelheim Int Behandlung von HLA-DR-assoziierter Immundefizienz mit Interferon-gamma
CN1194828A (zh) * 1998-04-22 1998-10-07 王卫东 具有协同作用的美洛西林和舒巴坦的药物组合物
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE60026618T2 (de) * 1999-12-30 2007-01-18 Intermune, Inc., Brisbane Gamma-ifn flüssigtropfenaerosol und verfahren

Also Published As

Publication number Publication date
US8673934B2 (en) 2014-03-18
JP2005525361A (ja) 2005-08-25
AU2003219016B2 (en) 2008-10-16
CA2478133A1 (en) 2003-09-12
CN1652785A (zh) 2005-08-10
MXPA04008573A (es) 2005-09-08
DE50310242D1 (de) 2008-09-11
RU2327454C2 (ru) 2008-06-27
ATE402702T1 (de) 2008-08-15
RU2004129591A (ru) 2005-09-20
US20050234089A1 (en) 2005-10-20
WO2003074057A1 (de) 2003-09-12
EP1480646A1 (de) 2004-12-01
EP1480646B1 (de) 2008-07-30
DK1480646T3 (da) 2008-11-24
AU2003219016A1 (en) 2003-09-16
BRPI0308256A2 (pt) 2016-06-21
ES2311093T3 (es) 2009-02-01
WO2003074057A8 (de) 2005-09-29
DE10218328A1 (de) 2003-09-25

Similar Documents

Publication Publication Date Title
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
IL172773A0 (en) Formulations for the treatment of arhritis conditions
MX2022001540A (es) Composiciones farmaceuticas y metodos para contrarrestar la cardiotoxicidad inducida por quimioterapia.
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
IL175781A0 (en) Methods and reagents for the treatment of inflammatory disorders
BRPI0413234A (pt) derivados de imidazola bicìclica contra flaviviridae
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
TW200503708A (en) Gyrase inhibitors and uses thereof
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
UA89220C2 (ru) Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
TW200730190A (en) New combination to treat liver fibrosis
PT1480646E (pt) Agentes anti-infecciosos e/ou imunomoduladores para terapia preventiva após acidentes vasculares cerebrais graves
MXPA03007380A (es) Derivados de imidazol 2-tio sustituidos y el uso de los mismos en la industria farmaceutica.
NO20062229L (no) Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er)
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
WO2004078180A3 (en) Naaladase inhibitors for treating opioid tolerance
WO2003065991A3 (en) N-substituted3-hydroxy-4-pyridinones and pharmaceuticals containing thereof
WO2003061704A3 (en) Combination therapy for the treatment of bacterial infections
BR0111785A (pt) Composições e métodos para tratamento de candidìase
EP1620061A4 (en) ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY CORONAVIRES
ME00550B (me) Korišćenje il-18 inhibitora za lećenje ili prevenciju povreda cns